Cost Insights: Breaking Down Amgen Inc. and ADMA Biologics, Inc.'s Expenses

Amgen vs. ADMA: A Decade of Cost Dynamics

__timestamp	ADMA Biologics, Inc.	Amgen Inc.
Wednesday, January 1, 2014	3742367	4422000000
Thursday, January 1, 2015	4311461	4227000000
Friday, January 1, 2016	6360761	4162000000
Sunday, January 1, 2017	29164321	4069000000
Monday, January 1, 2018	42194635	4101000000
Tuesday, January 1, 2019	39504238	4356000000
Wednesday, January 1, 2020	61291426	6159000000
Friday, January 1, 2021	79769341	6454000000
Saturday, January 1, 2022	118814535	6406000000
Sunday, January 1, 2023	169273000	8415000000
Monday, January 1, 2024		12858000000

Unleashing the power of data

Cost Insights: Amgen Inc. vs. ADMA Biologics, Inc.

In the ever-evolving landscape of biotechnology, understanding cost structures is crucial. This analysis delves into the cost of revenue for two industry players: Amgen Inc. and ADMA Biologics, Inc., from 2014 to 2023. Over this period, Amgen's cost of revenue consistently dwarfed that of ADMA, reflecting its larger scale and market presence. In 2023, Amgen's expenses surged to 8.4 billion, marking a 90% increase from 2014. Meanwhile, ADMA's costs grew exponentially, rising by over 4,400% to reach 169 million in 2023. This stark contrast highlights the differing growth trajectories and operational scales of these companies. While Amgen's costs reflect its established market dominance, ADMA's rapid increase underscores its aggressive expansion strategy. These insights provide a window into the financial dynamics shaping the biotech sector.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025